Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
- Status
- TERMINATED
- Phase
- PHASE4
Healthy, Immunized Communities Study
- Status
- COMPLETED
- Phase
- NA
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
- Status
- COMPLETED
- Phase
- PHASE1
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
- Status
- RECRUITING
- Phase
- N/A
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
- Status
- COMPLETED
- Phase
- PHASE3
Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
- Status
- UNKNOWN
- Phase
- PHASE4
Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
- Status
- COMPLETED
- Phase
- PHASE1
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
AO-176 in Multiple Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3